What is he best known for?
The fields of study he is best known for:
Philip Meuleman focuses on Virology, Hepatitis C virus, Virus, Immunology and Cell culture.
His Virology study frequently draws connections between adjacent fields such as Genotype.
His study in Hepatitis C virus is interdisciplinary in nature, drawing from both Liver transplantation, Transplantation, Viral hepatitis, Hepatitis C and Liver disease.
His work in Immunology addresses issues such as In vivo, which are connected to fields such as Viral disease, Internal medicine, Viral life cycle and Hepatology.
His Antibody research includes elements of Immune system and Immunity.
His Infectivity study combines topics from a wide range of disciplines, such as Receptor and Molecular biology.
His most cited work include:
- Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro (413 citations)
- Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. (313 citations)
- Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. (207 citations)
What are the main themes of his work throughout his whole career to date?
Philip Meuleman spends much of his time researching Virology, Hepatitis C virus, Immunology, Virus and In vivo.
Philip Meuleman combines subjects such as Genotype, Hepatitis E virus, Antibody, Monoclonal antibody and Transplantation with his study of Virology.
His studies deal with areas such as Hepatocellular carcinoma, Viral entry, Hepatitis C and Liver transplantation as well as Hepatitis C virus.
His biological study spans a wide range of topics, including Human liver and Liver disease.
His Virus study integrates concerns from other disciplines, such as Cell culture and Green fluorescent protein.
His In vivo study combines topics in areas such as In vitro, Hepatocyte, Drug metabolism, Metabolism and Plasmodium falciparum.
He most often published in these fields:
- Virology (69.18%)
- Hepatitis C virus (42.47%)
- Immunology (32.88%)
What were the highlights of his more recent work (between 2016-2021)?
- Virology (69.18%)
- Hepatitis E virus (13.70%)
- Hepatitis C virus (42.47%)
In recent papers he was focusing on the following fields of study:
His main research concerns Virology, Hepatitis E virus, Hepatitis C virus, Virus and Genotype.
His Virology research incorporates elements of Human liver and Antibody, Immunology, Antigen.
Philip Meuleman works mostly in the field of Immunology, limiting it down to concerns involving In vivo and, occasionally, Plasmodium falciparum.
His Hepatitis E virus research is multidisciplinary, incorporating elements of Ribavirin, Hepatitis E, Capsid and Transmission.
His research in Hepatitis C virus intersects with topics in Hepatitis C, Liver disease, Epitope, Monoclonal antibody and Transplantation.
In Virus, he works on issues like Chimera, which are connected to Vector.
Between 2016 and 2021, his most popular works were:
- Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver. (83 citations)
- Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein (69 citations)
- Tuning a cellular lipid kinase activity adapts hepatitis C virus to replication in cell culture. (35 citations)
In his most recent research, the most cited papers focused on:
Philip Meuleman mostly deals with Virology, Hepatitis E virus, Hepatitis C virus, Genotype and Ribavirin.
His work in the fields of Virology, such as Virus and Antiviral therapy, overlaps with other areas such as Small animal.
Many of his studies on Virus apply to Hepatitis C as well.
His work deals with themes such as Viral hepatitis, Hepatitis E, In vivo and Transmission, which intersect with Hepatitis E virus.
Philip Meuleman interconnects Hepatocellular carcinoma and Plasmodium falciparum infection in the investigation of issues within Hepatitis C virus.
His Genotype research includes themes of Human liver and Immunology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
